Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Sonja Zweegman, Claudia A M Stege, Einar Haukas, Fredrik H Schjesvold, Mark-David Levin, Anders Waage, Rineke B l Leys, Saskia K Klein, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Dorota Knut-Bojanowska, Ellen van der Spek, Asta Svirskaite, Anja Klostergaard, Morten Salomo, Celine Blimark, Paula F Ypma, Ulf-Henrik Mellqvist, Pino J PoddigheMarian Stevens-Kroef, Niels W C J van de Donk, Pieter Sonneveld, Markus Hansson, Bronno van der Holt, Niels Abildgaard

Research output: Contribution to journalLetterAcademicpeer-review

Original languageEnglish
Pages (from-to)2879-2882
Number of pages4
Issue number12
Publication statusPublished - Dec 2020
Externally publishedYes

Cite this